Steven I. Blum

1.7k total citations
49 papers, 478 citations indexed

About

Steven I. Blum is a scholar working on Economics and Econometrics, Pulmonary and Respiratory Medicine and Pharmacology. According to data from OpenAlex, Steven I. Blum has authored 49 papers receiving a total of 478 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Economics and Econometrics, 15 papers in Pulmonary and Respiratory Medicine and 12 papers in Pharmacology. Recurrent topics in Steven I. Blum's work include Health Systems, Economic Evaluations, Quality of Life (17 papers), Economic and Financial Impacts of Cancer (14 papers) and Renal cell carcinoma treatment (8 papers). Steven I. Blum is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (17 papers), Economic and Financial Impacts of Cancer (14 papers) and Renal cell carcinoma treatment (8 papers). Steven I. Blum collaborates with scholars based in United States, United Kingdom and Germany. Steven I. Blum's co-authors include Eric Q. Wu, Abhilasha Ramasamy, Andrew P. Yu, Michelle Mocarski, Juliana Setyawan, Donald M. Bushnell, Meryl Brod, David Cella, Hongbo Yang and Robyn T. Carson and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and The Lancet Oncology.

In The Last Decade

Steven I. Blum

44 papers receiving 471 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Steven I. Blum United States	12	185	113	94	89	47	49	478
Chakkarin Burudpakdee United States	13	92 0.5×	37 0.3×	71 0.8×	54 0.6×	80 1.7×	42	487
Álex de la Sierra Spain	12	94 0.5×	54 0.5×	251 2.7×	55 0.6×	32 0.7×	16	830
Barbara Peil Germany	10	83 0.4×	51 0.5×	43 0.5×	46 0.5×	18 0.4×	22	454
Robert Boggs United States	16	151 0.8×	194 1.7×	17 0.2×	57 0.6×	80 1.7×	34	1.2k
Breanne Lechner Canada	10	70 0.4×	43 0.4×	127 1.4×	75 0.8×	21 0.4×	19	409
Katharina Schmidt Germany	15	182 1.0×	151 1.3×	351 3.7×	34 0.4×	12 0.3×	40	752
Stephen P. Motsko United States	11	71 0.4×	29 0.3×	61 0.6×	87 1.0×	21 0.4×	23	637
Roberta Littleford United Kingdom	14	95 0.5×	154 1.4×	37 0.4×	28 0.3×	13 0.3×	39	632
Sachiko Tanaka‐Mizuno Japan	14	46 0.2×	94 0.8×	54 0.6×	24 0.3×	15 0.3×	55	520
Fausto Roila Italy	15	176 1.0×	95 0.8×	336 3.6×	17 0.2×	28 0.6×	44	800

Countries citing papers authored by Steven I. Blum

Since Specialization

Citations

This map shows the geographic impact of Steven I. Blum's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Steven I. Blum with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Steven I. Blum more than expected).

Fields of papers citing papers by Steven I. Blum

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Steven I. Blum. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Steven I. Blum. The network helps show where Steven I. Blum may publish in the future.

Co-authorship network of co-authors of Steven I. Blum

This figure shows the co-authorship network connecting the top 25 collaborators of Steven I. Blum. A scholar is included among the top collaborators of Steven I. Blum based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Steven I. Blum. Steven I. Blum is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lonardi, Sara, Dirk Arnold, Rocio García‐Carbonero, et al.. (2024). 2O Health-related quality of life (HRQoL) with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) in patients (pts) with microsatellite instability-high (MSI-H)/mismatch repair-deficient (dMMR) metastatic colorectal cancer (mCRC): CheckMate 8HW. Annals of Oncology. 35. S1–S2. 2 indexed citations

Chau, Ian, John Bridgewater, Lucjan Wyrwicz, et al.. (2024). A quality-adjusted time without symptoms and toxicity (Q-TWiST) analysis comparing nivolumab plus ipilimumab (N+I) or nivolumab plus chemotherapy (N+CT) versus CT in patients (pts) with advanced esophageal squamous cell carcinoma (ESCC): CheckMate 648.. Journal of Clinical Oncology. 42(3_suppl). 251–251.

Blum, Steven I., Jessica R. Miller, Kristin Bradley, et al.. (2024). Dosimetric evaluation of adaptive planning for five-fraction gynecologic template-based interstitial brachytherapy. Brachytherapy. 23(6). 668–675. 1 indexed citations

Sun, Virginia, Vineet K. Raghu, Chia‐Yun Wu, et al.. (2024). Abstract 4119426: Enhancing early detection of ICI myocarditis cases during hospitalization: A role for large language models. Circulation. 150(Suppl_1). 1 indexed citations

Cella, David, Toni K. Choueiri, Steven I. Blum, et al.. (2023). Health-related quality of life (HRQoL) of risk-based patient subgroups with advanced renal cell cancer (aRCC) treated with nivolumab plus cabozantinib (NIVO+CABO) vs sunitinib (SUN) in the CheckMate 9ER trial.. Journal of Clinical Oncology. 41(16_suppl). 4527–4527.

Mathias, Susan D., et al.. (2020). Symptoms and impacts in anemia of chronic kidney disease. Journal of Patient-Reported Outcomes. 4(1). 64–64. 19 indexed citations

Edeline, Julien, Thomas Yau, Joong‐Won Park, et al.. (2020). CheckMate 459: Health-related quality of life (HRQoL) in a randomized, multicenter phase III study of nivolumab (NIVO) versus sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC).. Journal of Clinical Oncology. 38(4_suppl). 483–483. 26 indexed citations

Reck, Martin, T-E. Ciuleanu, Manuel Cobo, et al.. (2020). LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA. Annals of Oncology. 31. S1187–S1188. 5 indexed citations

Martin, Mona L., et al.. (2019). Development and adaptation of patient-reported outcome measures for patients who experience itch associated with primary biliary cholangitis. Journal of Patient-Reported Outcomes. 3(1). 2–2. 8 indexed citations

10.

Bushnell, Donald M., Steven I. Blum, Hiltrud Liedgens, et al.. (2018). Mixed-methods development of a new patient-reported outcome instrument for chronic low back pain: part 2—The Patient Assessment for Low Back Pain–Impacts (PAL-I). Pain. 159(10). 2066–2075. 7 indexed citations

11.

Houts, Carrie R., Robert Morlock, Steven I. Blum, Michael C. Edwards, & R. Wirth. (2018). Scale development with small samples: a new application of longitudinal item response theory. Quality of Life Research. 27(7). 1721–1734. 9 indexed citations

12.

Taylor, Douglas C.A., et al.. (2016). Economic Evaluation of Linaclotide for the Treatment of Adult Patients With Chronic Idiopathic Constipation in the United States.. PubMed. 25(2). 41–8. 3 indexed citations

13.

Blum, Steven I., Stavros Tourkodimitris, & Adam Ruth. (2014). Evaluation of functional health and well-being in patients receiving levomilnacipran ER for the treatment of major depressive disorder. Journal of Affective Disorders. 170. 230–236. 13 indexed citations

14.

Taylor, Douglas C.A., et al.. (2014). Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States. Journal of Medical Economics. 18(4). 283–294. 10 indexed citations

15.

Hayes, Risa P., Steven I. Blum, Mark Forrest Gordon, et al.. (2014). The Patient-Reported Outcome (PRO) Consortium: Lessons Learned Along the Path to PRO Instrument Qualification. Therapeutic Innovation & Regulatory Science. 49(1). 132–138. 7 indexed citations

16.

Blum, Steven I., et al.. (2012). P.2.c.022 Levomilnacipran in the treatment of major depressive disorder: functional health and well-being efficacy results from a phase III trial. European Neuropsychopharmacology. 22. S262–S263. 1 indexed citations

17.

Yu, Andrew P., Annie Guérin, Karthik Ramakrishnan, et al.. (2011). Clinical and economic outcomes of multiple versus single long-acting inhalers in COPD. Respiratory Medicine. 105(12). 1861–1871. 42 indexed citations

18.

Yu, Andrew P., Hongbo Yang, Eric Q. Wu, et al.. (2011). Incremental third-party costs associated with COPD exacerbations: a retrospective claims analysis. Journal of Medical Economics. 14(3). 315–323. 53 indexed citations

19.

Yu, Andrew P., Rym Ben-Hamadi, Eric Q. Wu, et al.. (2011). Impact of initiation timing of SSRI or SNRI on depressed adolescent healthcare utilization and costs. Journal of Medical Economics. 14(4). 508–515. 6 indexed citations

20.

Yu, Andrew P., Jipan Xie, Arielle G. Bensimon, et al.. (2010). Economic consequence of switching to citalopram after its generic entry for adult patients with major depressive disorder (MDD) treated with escitalopram: a 6-month retrospective study. Journal of Medical Economics. 13(4). 599–609. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact